Skip to content
OpenCapital
Get started

Revolution Medicines, Inc. RVMD Fair Value Adjustment Of Warrants

Other financials

Income statement

See full
Revenue-—
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$34.65B+193%
Enterprise value$34.37B+198%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s fair value adjustment of warrants.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revolution Medicines, Inc.'s fair value adjustment of warrants?
Revolution Medicines, Inc. (RVMD) reported fair value adjustment of warrants of $15.79M in Q1 2026.
How has Revolution Medicines, Inc.'s fair value adjustment of warrants changed year-over-year?
Revolution Medicines, Inc.'s fair value adjustment of warrants increased by 747.3% year-over-year, from -$2.44M to $15.79M.